Angelini Ventures

What they do

Angelini Ventures was established in October 2022 as the corporate venture capital initiative of Angelini Industries, a multi-sector Italian industrial group that has been operating since 1919. Backed by an initial €300 million evergreen capital commitment, the firm is positioned as a key pillar of healthcare innovation, operating with a dual mandate: generating financial returns and driving strategic diversification for its parent company. Unlike traditional CVCs that strictly seek immediate synergies with their parent's core business, Angelini Ventures operates with a broader "open innovation" approach, investing in disruptive technologies that will transform the global health system over the next 10 to 20 years. They have built a strong reputation in the European and North American ecosystems, recently bolstered by a landmark €150 million co-investment agreement with the European Investment Bank (EIB).

What they look for

Angelini Ventures aims to "shape the future of care" by building and investing in early-stage companies that develop innovative ideas and solutions in biotechnology, digital health, and life sciences. They focus on leveraging technology to improve healthcare, reshape patient journeys, and address unmet medical needs. The firm looks for disruptive innovations, novel science, and evidence-based solutions. They have a specific strategic focus on brain health, the central nervous system (CNS), and consumer segments involving vulnerable populations such as women, children, and the elderly.

Stage

Pre-seed, Seed, Series A, Series B+

Sectors

Healthcare

Based

Rome, IT